115 Leukemia Clinical Trials in Boston, NY (2026)

Q: Are there leukemia clinical trials in Boston?

Yes, there are 115 leukemia clinical trials currently recruiting in Boston, NY.

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Q: Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Leukemia Studies in Boston

NCT04028531Recruiting

Understanding Chronic Lymphocytic Leukemia

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemi...

Boston, NY2,750 participantsDana-Farber Cancer Institute

View Study Details

NCT05237258Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcome...

Boston, NY2,300 participantsMassachusetts General Hospital

View Study Details

NCT04165798Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a...

Boston, NY1,065 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05384626Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activ...

Boston, NY840 participantsNuvalent Inc.

View Study Details

NCT05379985Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Boston, NY754 participantsRevolution Medicines, Inc.

View Study Details

NCT06487247Recruiting

HEME Home Transfusion Program

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quali...

Boston, NY700 participantsDana-Farber Cancer Institute

View Study Details

NCT06917079Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumo...

Boston, NY665 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT04988555Recruiting

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia....

Boston, NY606 participantsSumitomo Pharma America, Inc.

View Study Details

NCT06040541Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors....

Boston, NY604 participantsRevolution Medicines, Inc.

View Study Details

NCT06615050Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

Boston, NY572 participantsIncyte Corporation

View Study Details

NCT05786924Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combin...

Boston, NY554 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Boston, NY500 participantsStanford University

View Study Details

NCT07100080Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy...

Boston, NY500 participantsBristol-Myers Squibb

View Study Details

NCT05265429Recruiting

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger....

Boston, NY500 participantsDana-Farber Cancer Institute

View Study Details

NCT04165070Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

Boston, NY450 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05581004Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizum...

Boston, NY450 participantsGenentech, Inc.

View Study Details

NCT04065399Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

Boston, NY447 participantsSyndax Pharmaceuticals

View Study Details

NCT04811560Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 ...

Boston, NY420 participantsJanssen Research & Development, LLC

View Study Details

NCT07111520Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treat...

Boston, NY420 participantsBioNTech SE

View Study Details

NCT04759443Recruiting

Detection of Small Fiber Neuropathy Using Skin Properties

Small fiber neuropathy affects millions of peoples worldwide. The neuropathy is causing disabling burning pain and dysautonomia such as dizziness with standing, brain fog, fatigue, constipation, too m...

Boston, NY400 participantsBrigham and Women's Hospital

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Boston, NY400 participantsBayer

View Study Details

NCT07037758Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to...

Boston, NY380 participantsAmgen

View Study Details

NCT06780137Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

Boston, NY327 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

Boston, NY316 participantsTaiho Oncology, Inc.

View Study Details

NCT06406114Recruiting

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of...

Boston, NY300 participantsMassachusetts General Hospital

View Study Details

NCT04968834Recruiting

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part...

Boston, NY300 participantsDana-Farber Cancer Institute

View Study Details

NCT06876662Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

Boston, NY279 participantsEli Lilly and Company

View Study Details

NCT03824483Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and ven...

Boston, NY230 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05967689Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring...

Boston, NY220 participantsTaiho Oncology, Inc.

View Study Details

NCT05475925Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

Boston, NY200 participantsDren Bio

View Study Details

NCT06472128Recruiting

Novel Digital Application for Patients With Acute Leukemia

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes fo...

Boston, NY200 participantsMassachusetts General Hospital

View Study Details

NCT06521554Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in parti...

Boston, NY200 participantsNuvalent Inc.

View Study Details

NCT07155174Recruiting

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, a...

Boston, NY180 participantsAbbVie

View Study Details

NCT05362773Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have...

Boston, NY130 participantsMacroGenics

View Study Details

NCT06667908Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

Boston, NY130 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT06855771Recruiting

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion ...

Boston, NY130 participantsBristol-Myers Squibb

View Study Details

NCT06533761Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effi...

Boston, NY125 participantsStelexis BioSciences

View Study Details

NCT07006727Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged...

Boston, NY116 participantsNovartis Pharmaceuticals

View Study Details

NCT06950034Recruiting

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no furthe...

Boston, NY105 participantsSolu Therapeutics, Inc

View Study Details

NCT06419634Recruiting

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine an...

Boston, NY105 participantsBristol-Myers Squibb

View Study Details

NCT07220811Recruiting

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generat...

Boston, NY100 participantsRAPT Therapeutics, Inc.

View Study Details

NCT06451497Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standar...

Boston, NY100 participantsZumutor Biologics Inc.

View Study Details

NCT06561360Recruiting

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will...

Boston, NY86 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06150664Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Do...

Boston, NY85 participantsCompass Therapeutics

View Study Details

NCT06456463Recruiting

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azaci...

Boston, NY83 participantsStemline Therapeutics, Inc.

View Study Details

NCT07024706Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi +...

Boston, NY80 participantsAstraZeneca

View Study Details

NCT04895436Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

Boston, NY75 participantsAbbVie

View Study Details

NCT05473910Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminar...

Boston, NY75 participantsTScan Therapeutics, Inc.

View Study Details

NCT06907797Recruiting

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resour...

Boston, NY75 participantsDana-Farber Cancer Institute

View Study Details

NCT06707493Recruiting

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell tran...

Boston, NY75 participantsMassachusetts General Hospital

View Study Details

NCT03113643Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax...

Boston, NY72 participantsDana-Farber Cancer Institute

View Study Details

NCT07149363Recruiting

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC)....

Boston, NY65 participantsAlliance Foundation Trials, LLC.

View Study Details

NCT06644183Recruiting

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphoc...

Boston, NY64 participantsJennifer R. Brown, MD, PhD

View Study Details

NCT07015996Recruiting

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for t...

Boston, NY62 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05621291Recruiting

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may ...

Boston, NY60 participantsNational Cancer Institute (NCI)

View Study Details

NCT06333262Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphoc...

Boston, NY60 participantsInhye Ahn

View Study Details

NCT05236153Recruiting

Electroanatomic Interactions Between Transcatheter Pulmonary Valve Prostheses and Anatomic Isthmuses in Repaired Tetralogy of Fallot

Individuals with repaired Tetralogy of Fallot (rTOF) remain at risk for sudden cardiac death from ventricular tachycardia (VT). Transcatheter pulmonary valve replacement (TPVR) indications continue to...

Boston, NY60 participantsBoston Children's Hospital

View Study Details

NCT07553572Recruiting

Remote Monitoring and Symptom Management Digital Application

The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The main question\[s\] it aims to answer are: ...

Boston, NY60 participantsPatrick C. Johnson, MD

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Boston, NY60 participantsCullinan Therapeutics Inc.

View Study Details

NCT06484062Recruiting

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplast...

Boston, NY54 participantsNational Cancer Institute (NCI)

View Study Details

NCT06660368Recruiting

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measur...

Boston, NY52 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Boston, NY52 participantsCellectis S.A.

View Study Details

NCT05546580Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat ...

Boston, NY50 participantsOryzon Genomics S.A.

View Study Details

NCT04024761Recruiting

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysp...

Boston, NY50 participantsDana-Farber Cancer Institute

View Study Details

NCT07020533Recruiting

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremi...

Boston, NY46 participantsCity of Hope Medical Center

View Study Details

NCT05168930Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lympho...

Boston, NY45 participantsDana-Farber Cancer Institute

View Study Details

NCT03104491Recruiting

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects ...

Boston, NY44 participantsLeland Metheny

View Study Details

NCT07184476Recruiting

Assessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient

The pediatric cardiac surgery patient endures a tremendous number of physiologic alterations during surgery and cardiopulmonary bypass (CPB) that lasts well into the recovery period. Most of the hemod...

Boston, NY40 participantsBoston Children's Hospital

View Study Details

NCT03595917Recruiting

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is...

Boston, NY40 participantsMarlise Luskin, MD

View Study Details

NCT06160752Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including un...

Boston, NY40 participantsTyra Biosciences, Inc

View Study Details

NCT06849713Recruiting

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small...

Boston, NY40 participantsMassachusetts General Hospital

View Study Details

NCT05019703Recruiting

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the b...

Boston, NY40 participantsM.D. Anderson Cancer Center

View Study Details

NCT07052695Recruiting

Mosunetuzumab for CLL MRD Clearance

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in partic...

Boston, NY40 participantsInhye Ahn

View Study Details

NCT04560322Recruiting

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in thi...

Boston, NY40 participantsMassachusetts General Hospital

View Study Details

NCT05796570Recruiting

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodyspla...

Boston, NY37 participantsFranziska Wachter

View Study Details

NCT05695261Recruiting

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the invest...

Boston, NY37 participantsRima Rachid

View Study Details

NCT06247787Recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic sy...

Boston, NY36 participantsChildren's Oncology Group

View Study Details

NCT05271292Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...

Boston, NY36 participantsChipscreen Biosciences, Ltd.

View Study Details

NCT04925479Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...

Boston, NY34 participantsNovartis Pharmaceuticals

View Study Details

NCT07148180Recruiting

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is...

Boston, NY31 participantsJacqueline Garcia, MD

View Study Details

NCT04972942Recruiting

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell trans...

Boston, NY30 participantsNew York Medical College

View Study Details

NCT07374029Recruiting

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard ...

Boston, NY30 participantsDavid Avigan

View Study Details

NCT05592015Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the...

Boston, NY30 participantsJonathan Brammer

View Study Details

NCT06943534Recruiting

Omalizumab Weight-Based Dosing Efficacy Trial

This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies....

Boston, NY30 participantsMassachusetts General Hospital

View Study Details

NCT05703542Recruiting

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The name...

Boston, NY24 participantsEric Stephen Winer, MD

View Study Details

NCT06440135Recruiting

Ziftomenib Maintenance Post Allo-HCT

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoiet...

Boston, NY22 participantsMassachusetts General Hospital

View Study Details

NCT06313437Recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted th...

Boston, NY22 participantsRichard Stone, MD

View Study Details

NCT05335434Recruiting

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (all...

Boston, NY20 participantsDana-Farber Cancer Institute

View Study Details

NCT06376162Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or...

Boston, NY20 participantsPedAL BCU, LLC

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Boston, NY20 participantsAdaptimmune

View Study Details

NCT07061951Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (...

Boston, NY20 participantsNational Cancer Institute (NCI)

View Study Details

NCT04704323Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e....

Boston, NY18 participantsCatapult Therapeutics

View Study Details

NCT07315113Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)...

Boston, NY18 participantsNuvectis Pharma, Inc.

View Study Details

NCT07447869Recruiting

LYmph Node eXamination in Cat Allergen Immunotherapy

Sixteen eligible cat-allergic participants will be accrued in the study. Eight participants who have been on subcutaneous immunotherapy (SCIT) at maintenance dosing for at least 1 year will be assigne...

Boston, NY16 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT03219450Recruiting

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personal...

Boston, NY15 participantsDana-Farber Cancer Institute

View Study Details

NCT06138587Recruiting

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute...

Boston, NY15 participantsDana-Farber Cancer Institute

View Study Details

NCT05452720Recruiting

MASA Valve Early Feasibility Study

The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is t...

Boston, NY10 participantsPECA Labs

View Study Details

NCT06931626Recruiting

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to eva...

Boston, NY10 participantsNerviano Medical Sciences

View Study Details

NCT06152809Recruiting

CIML NK Cells With Venetoclax for AML

The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (...

Boston, NY10 participantsDana-Farber Cancer Institute

View Study Details

NCT06284486Recruiting

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML....

Boston, NY8 participantsM.D. Anderson Cancer Center

View Study Details

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or...

Boston, NY574 participantsRevolution Medicines, Inc.

View Study Details

NCT06128551Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors....

Boston, NY534 participantsRevolution Medicines, Inc.

View Study Details

NCT06104566Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who pr...

Boston, NY400 participantsAscentage Pharma Group Inc.

View Study Details

NCT06859424Recruiting

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The so...

Boston, NY358 participantsCenter for International Blood and Marrow Transplant Research

View Study Details

NCT06697184Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies....

Boston, NY258 participantsBeiGene

View Study Details

NCT07046923Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the blood...

Boston, NY240 participantsEli Lilly and Company

View Study Details

NCT07458347Recruiting

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutatio...

Boston, NY145 participantsKestrel Therapeutics, Inc.

View Study Details

NCT04215809Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax....

Boston, NY144 participantsAscentage Pharma Group Inc.

View Study Details

NCT06218914Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors....

Boston, NY108 participantsAstraZeneca

View Study Details

NCT03471260Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutate...

Boston, NY96 participantsM.D. Anderson Cancer Center

View Study Details

NCT04900935Recruiting

Patient-centered, Optimal Integration of Survivorship and Palliative Care

The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE fea...

Boston, NY70 participantsMassachusetts General Hospital

View Study Details

NCT03779854Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant....

Boston, NY68 participantsFred Hutchinson Cancer Center

View Study Details

NCT03936998Recruiting

VE416 for Treatment of Food Allergy

This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone....

Boston, NY60 participantsMassachusetts General Hospital

View Study Details

NCT05877599Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors....

Boston, NY45 participantsAstraZeneca

View Study Details

NCT06469307Recruiting

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review...

Boston, NY40 participantsDana-Farber Cancer Institute

View Study Details

About Leukemia Clinical Trials in Boston

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 115 leukemia clinical trials recruiting participants in Boston, NY. These studies are seeking a combined 25,679 participants. Research is being sponsored by Dana-Farber Cancer Institute, Massachusetts General Hospital, Merck Sharp & Dohme LLC and 68 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Boston — FAQ

Are there leukemia clinical trials in Boston?

Yes, there are 115 leukemia clinical trials currently recruiting in Boston, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 115 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 13, 2026 from ClinicalTrials.gov